Neck News and Research

RSS

ASTRO honors founder of The Oral Cancer Foundation

The American Society for Radiation Oncology (ASTRO) has named Brian Hill of Newport Beach, Calif., as its 2010 Survivor Circle Award winner. Hill will be recognized with a trophy and a $1,000 prize during the Awards Ceremony on Tuesday, November 2, 2010, during ASTRO's 52nd Annual Meeting in San Diego. He has chosen to donate the funds from the award to benefit The Oral Cancer Foundation, the nonprofit he started a decade ago.

18 Oct 2010

Botox receives FDA approval for treatment of chronic migraine

The U.S. Food and Drug Administration today approved Botox injection (onabotulinumtoxinA) to prevent headaches in adult patients with chronic migraine. Chronic migraine is defined as having a history of migraine and experiencing a headache on most days of the month.

18 Oct 2010

Genmab provides update on potential regulatory pathway for zalutumumab

Genmab A/S announced today an update on the potential regulatory pathway for zalutumumab following preliminary, non-binding discussions with a number of selected national European regulatory authorities and the FDA.

18 Oct 2010

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast (zoledronic acid) injection in postmenopausal women with osteoporosis. The study of more than 1,200 women was presented this weekend at the annual meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, ON, Canada.

18 Oct 2010

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

Allergan, Inc. today announced the United States Food and Drug Administration (FDA) has approved BOTOX(onabotulinumtoxinA) for the prophylactic (preventive) treatment of headaches in adults with Chronic Migraine.

18 Oct 2010

Applied Skin Technology launches three revolutionary products for skin damage

Applied Skin Technology announces the launch of three breakthrough moisturizers, harnessing cutting-edge skin care technology, and using the most effective skin restoring ingredients available. These revolutionary products are formulated for three different categories: women, men, and a recovery cream for skin that has been damaged due to a medical condition or the side effect of medical treatment.

15 Oct 2010

First Edition: October 14, 2010

Today's headlines examine the Obama administration's efforts to work with insurers to keep coverage options for children, the latest campaign news on the health overhaul and a major government crackdown on a Medicare fraud ring.

14 Oct 2010

Tiger Balm sponsors 15th annual Susan G. Komen Miami/Ft. Lauderdale Race for the Cure

Tiger Balm announced today its sponsorship of the 15th annual Susan G. Komen Miami/Ft. Lauderdale Race for the Cure®, taking place Saturday, October 16, 2010 in Miami's Bayfront Park.

14 Oct 2010

IsoRay initiates study of Cesium-131 brachytherapy seeds for NSCLC cancer

IsoRay, Inc. announced today the initiation of a multi-institutional study of Cesium-131 brachytherapy seeds (internal radiation therapy) for use in Non Small Cell Lung Cancers (NSCLC). A number of institutions and physicians will be working to collect scientific data to further the use of Cesium-131 internal radiation therapy in conjunction with surgery for NSCLC.

14 Oct 2010

Humanitas Clinic treats first cancer patient using TrueBeam technology

A 54-year-old head & neck cancer patient has become the first person in Italy to be treated using a revolutionary new linear accelerator that can deliver radiotherapy twice as fast as conventional therapy machines. The Humanitas Clinic in Rozzano-Milan carried out the treatment last week, becoming only the third hospital in Europe to begin clinical treatments using TrueBeam from Varian Medical Systems.

13 Oct 2010

CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation announced today it has received approval from the first Taiwanese Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Oct 2010

Proper treatment for scoliosis may help children to lead active lives

Scoliosis may sound like a frightening diagnosis, but proper treatment enables children with the condition to lead normal, active lives. Scoliosis refers to an abnormal curvature of the spine. Small curves are a normal part of spine anatomy and are not cause for concern, according to Dr. Daniel Green, a pediatric orthopedic surgeon at Hospital for Special Surgery in Manhattan. But when the curvature exceeds a certain range, children require medical attention.

12 Oct 2010

Access highlights clinical benefits of MuGard at ESMO conference

Access Pharmaceuticals, Inc., a biopharmaceutical company specializing in products for cancer and supportive care, announced the highlights from a poster presentation on European clinical experience of MuGard at this year's European Society of Medical Oncology Conference in Milan, Italy.

11 Oct 2010

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced the first results from the BALI-1 study of Erbitux® (cetuximab) in the treatment of metastatic triple-negative breast cancer (TNBC), an aggressive cancer in which early relapse and metastasis are common. The data, presented during the 35th Congress of the European Society for Medical Oncology (ESMO), demonstrate that Erbitux has the potential to improve outcomes for women with this relentlessly devastating cancer.

11 Oct 2010

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

Boehringer Ingelheim Pharmaceuticals, Inc. announced today results from two clinical trials for its investigational cancer compound afatinib* (BIBW 2992) presented at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy.

11 Oct 2010

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Eli Lilly and Company announced today that its global Phase III trial evaluating ALIMTA (pemetrexed for injection) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (SCCHN) did not meet its primary endpoint for overall survival. Data were presented for the first time today at the 35th Annual Meeting of the European Society for Medical Oncology (ESMO).

11 Oct 2010

Researchers find significant difference between prevalence of tinnitus among elderly people

Tinnitus is common among elderly Nigerians and associated with treatable health conditions like otitis media, rhinosinusitis, head injury and hypertension, according to new research published in the October 2010 issue of Otolaryngology - Head and Neck Surgery.

8 Oct 2010

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

Advanced Medical Isotope Corporation, a company engaged in the production and distribution of medical isotopes, is delighted to announce the execution of an exclusive world-wide license for patented technology for a proprietary brachytherapy seed with a fast-dissolving matrix for optimized delivery of radionuclides to cancer tissue.

7 Oct 2010

Cs-131 brachytherapy seed implant can treat metastasized cancer

IsoRay, Inc. announced today another milestone in the use of Cesium-131 (Cs-131) brachytherapy seeds (internal radiation therapy). Doctors at a world renowned medical facility have performed the world's first Cs-131 brachytherapy seed implant following a wedge resection of a lung tumor which originated from a form of malignant uterine cancer. Initially used to treat primary cancers, Cs-131 seeds are now being used to treat metastasized cancer.

7 Oct 2010

Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers

A vaccine that turns the immune system against brain tumor cells bearing a genetic mutation that drives the most aggressive form of glioblastoma multiforme improved survival of patients in a phase II clinical trial, researchers at Duke University and The University of Texas MD Anderson Cancer Center reported today in the Journal of Clinical Oncology.

7 Oct 2010

Neck News and Research

ASTRO honors founder of The Oral Cancer Foundation

Botox receives FDA approval for treatment of chronic migraine

Genmab provides update on potential regulatory pathway for zalutumumab

Six-year data of reinforces efficacy and safety of Reclast injection in postmenopausal women with osteoporosis

FDA approves BOTOX as prophylactic treatment for Chronic Migraine

Applied Skin Technology launches three revolutionary products for skin damage

First Edition: October 14, 2010

Tiger Balm sponsors 15th annual Susan G. Komen Miami/Ft. Lauderdale Race for the Cure

IsoRay initiates study of Cesium-131 brachytherapy seeds for NSCLC cancer

Humanitas Clinic treats first cancer patient using TrueBeam technology

CEL-SCI receives Taiwanese IRB approval for Multikine Phase III trial in head and neck cancer

Proper treatment for scoliosis may help children to lead active lives

Access highlights clinical benefits of MuGard at ESMO conference

Merck Serono announces first results from Erbitux BALI-1 study in metastatic triple-negative breast cancer

Boehringer Ingelheim announces results from afatinib clinical trials at 35th ESMO

Eli Lilly presents ALIMTA Phase III trial results at ESMO Annual Meeting

Researchers find significant difference between prevalence of tinnitus among elderly people

AMIC signs world-wide license for brachytherapy seed with fast-dissolving matrix

Cs-131 brachytherapy seed implant can treat metastasized cancer

Vaccine improves survival of glioblastoma patients in phase II clinical trial: Researchers

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News